CEO of activist hedge fund Starboard: 'We are certainly interested in the story at Bristol-Myers'

Smith refused to comment on a weekend report about Starboard taking a stake in the embattled pharmaceutical giant, which last month agreed to buy troubled cancer drug company Celgene in a cash and stock deal valued at $74 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.